Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (Pnet): A Study Of Morbidity And Mortality At 2 Years

Trial Profile

Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (Pnet): A Study Of Morbidity And Mortality At 2 Years

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Sunitinib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms OPALINE
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 02 May 2016 Status changed from recruiting to not yet recruiting.
    • 08 Feb 2016 Planned number of patients changed from 170 to 150 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top